SCHEMBL3109712

SCHEMBL3109712

CCN(CC)CCNC(=O)c1ccc(OC2CCC(=Cc3ccc(-c4ccccc4)cc3)CC2)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 4/20 0.45
TMEM97 Q5BJF2 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPT P10636 2/20 0.42
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
AKT1 P31749 2/20 0.40
AKT2 P31751 2/20 0.40
AKT3 Q9Y243 2/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13158778 0.92 HPGD (0.44) MCHR1TMEM97SIGMAR1MAPTKMT2A
SCHEMBL13158835 0.86 MCHR1 (0.49) MCHR1MAPTKMT2AMEN1TDP1
SCHEMBL13158798 0.85 SIGMAR1 (0.57) TMEM97SIGMAR1
SCHEMBL3110870 0.84 MCHR1 (0.45) MCHR1TMEM97SIGMAR1CYP3A4CYP2C9
SCHEMBL12437799 0.83 AKT1 (0.54) KMT2AMEN1AKT1AKT2AKT3
SCHEMBL13158777 0.83 SLC6A2 (0.46) MCHR1KMT2ADRD2DRD3
SCHEMBL13158793 0.82 IGF1R (0.38) MCHR1SIGMAR1CYP3A4CYP2C9MAPT
SCHEMBL12437919 0.81 TP53 (0.48)
SCHEMBL3115388 0.81 CYP3A4 (0.43) CYP3A4MAPTKMT2AMEN1PDE4A
SCHEMBL3116143 0.81 EPHX2 (0.48) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
EP-2141994-A1 MULTI-RING COMPOUNDS AND USES THEREOF Avalon Pharmaceuticals (US) 2010-01-13 EP disclosed
WO-2008133975-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2008-11-06 WO disclosed
WO-2008133975-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF TP53, BCOR, HPGDS MCHR1 4555/4885TMEM97 3194/4885SIGMAR1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.